Agoracom Blog Home

Author Archive

« Older Entries
Newer Entries »

PyroGenesis $PYR.ca Provides Update on Payment Terms with Drosrite International LLC $LMT $RTN $NOC $UTX $HPQ.ca $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 1:23 PM on Wednesday, February 26th, 2020
  • Announced today that, further to its press release dated October 9th, 2019, the payment terms noted therein have been adjusted pro rata to mirror Drosrite International LLC’s cash flow as outlined in their press release1 dated January 27th, 2020. 
  • “With this announcement, I am happy to also report that it seems all impediments to the payment process have been addressed,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “We look forward to having the DROSRITE™ technology installed in one of the premier facilities in the world.”

MONTREAL, Feb. 26, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, announces today that, further to its press release dated October 9th, 2019, the payment terms noted therein have been adjusted pro rata to mirror Drosrite International LLC’s (“DI” or the “Client”) cash flow as outlined in their press release1 dated January 27th, 2020. 

“With this announcement, I am happy to also report that it seems all impediments to the payment process have been addressed,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “We look forward to having the DROSRITE™ technology installed in one of the premier facilities in the world.”

DI is a US based private company duly constituted and existing under the laws of the State of Delaware, providing state-of-the-art waste management technologies to the aluminum industry. DI is duly licensed by PyroGenesis to manufacture, market, sell and distribute DROSRITE™ systems and technology to the Kingdom of Saudi Arabia, and certain other countries in the Middle East, on an exclusive basis. All DROSRITE™ systems supplied by DI are manufactured in the USA.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

For further information please contact:

Rodayna Kafal, Vice President Investors Relations and Strategic Business Development
Phone: (514) 937-0002, E-mail: [email protected]

RELATED LINK: http://www.pyrogenesis.com/

__________________________

Tags: , , ,
Posted in PyroGenesis Canada Inc. | Comments Off on PyroGenesis $PYR.ca Provides Update on Payment Terms with Drosrite International LLC $LMT $RTN $NOC $UTX $HPQ.ca $DDD.ca $SSYS $PRLB

Empower Clinics $CBDT.ca – CBD Sales Predicted to Grow, #cannabis and #cannabidiol #CBD products reached $14 billion in 2019 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 12:05 PM on Wednesday, February 26th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network

CBD Sales Predicted to Grow, Market Analysis Finds

  • U.S. retail sales of cannabis and cannabidiol (CBD) products reached $14 billion in 2019
  • On pace to increase 18% per year to $33 billion in 2024

By WholeFoods Magazine Staff

Rockville, MD—U.S. retail sales of cannabis and cannabidiol (CBD) products reached $14 billion in 2019, and are on pace to increase 18% per year to $33 billion in 2024, according to data published in a new report from Packaged Facts titled Cannabis and CBD: U.S. Retail Market Trends and Opportunities.

The most common delivery format for cannabis, the flower—smoked as buds or as cigarettes—accounts for nearly 40% of retail sales, according to a press release. Vaporizer cartridges with concentrated THC or CBD compounds takes the second largest share, but it’s falling, as concerns about vaping-related lung illnesses rise. Edibles and topicals are predicted to rise, and to rise quickly, as they stand to benefit the most from legalization of hemp-based CBD; major retailers are already offering CBD-infused food and beverages, as well as CBD-infused cosmetics.

The report analyzes cannabis and cannabis-related retail trends and opportunities in the U.S., with a focus on multi-state cannabis dispensary operators and food and beverage introductions, as well as market trends by state. It also includes a detailed analysis of cannabis-related legal and regulatory trends at the federal and state levels. The report can be purchased here.

Source: https://wholefoodsmagazine.com/suppliers/news-suppliers/cbd-sales-predicted-to-grow-market-analysis-finds/

Tags: , , , , , , ,
Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca – CBD Sales Predicted to Grow, #cannabis and #cannabidiol #CBD products reached $14 billion in 2019 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

AGORACOM Welcomes Hollister Biosciences With A $20 MILLION LOI Signed To Acquire Venom Extracts With $CDN 16.4 million In Revenue and $CN 2.48 million in EBIDTA

Posted by AGORACOM-JC at 6:39 PM on Tuesday, February 25th, 2020

HOLL:CSE / HOB:FRA

 www.hollistercannabisco.com

BREAKING: Signed $20,000,000 Letter of Intent To Acquire Venom Extracts (“Venom”)

HIGHLY ACCRETIVE $20,000,000 ACQUISITION

Venom Highlights

  • 2019 Est Revenue ~C$16.4M; EBITDA ~C$2.48M
  • 30% Of Acquisition Price Paid If Venom Revenues Hit $30,000,000 and $40,000,000 By DEC 31, 2021
  • Average revenue per gram YTD 2019 $CDN 14 and will continue to increase as vape cartridge mix grows ($CDN 30 per gram)
  • One Of Arizona’s Largest Producers Of Award-Winning Medical Cannabis Distillate
  • Acquisition Expected To Close By March 31, 2020 Subject To Due Dilligence

An established brand in Arizona for high quality products in the wholesale and distillate marketplace. Venom is leveraging its brand and success to aggressively expand into other US states.

ACQUISITION TERMS

  • Hollister will acquire Venom Extracts for CDN$20,000,000 via Hollister stock
  • The stock price will be determined based on the greater of:
    • The 14-day VWAP (Volume Weighted Average Price) capped at $0.25 subsequent to announcing the transaction and $0.20
    • Once share price is established, 70% of the Payment Shares will be issued upon closing of the transaction
    • Remaining 30% of the Payment Shares will be issued when and if the following milestones have been met on or prior to December 31st, 2021

Hollister Highlights Of Current Operations:

  • Hollister’s products are now present in 220 of 600 California dispensaries.
  • Own’s California’s #1 hash infused pre-roll “HashBone”
  • Vision is to capitalize on this success to become the sought after premium brand portfolio of Cannabis across multiple states and Hemp nationwide
  • Major LOI, Joint Ventures and Licensing Agreements Support Proof Of This Vision
  • “Easy Riders” – Milliions Of Global Followers
  • “Tactical Relief” – Veteran Founded, Hemp Based CBD Brand With Nation Wide Members  
  • “Tommy Chong” – Exclusive Manufacture & Distribution Of Tommy Chong’s Cannabis (TM) Full Spectrum Elixir 1:1

“I only partner with the best-in-class companies and I am really pleased to have the Hollister Cannabis Co. bring their amazing Tommy Chong’s Cannabis™ Full Spectrum Elixir to the market for me”. 

– Tommy Chong

KEY JOINT VENTURES AND PARTNERSHIPS DETAILS 

LOI for a proposed offtake agreement with Mountain Financial Solutions LLC 

  • Hollister will purchase 1,000 pounds of hemp from Mountain Financial (unique high CBD hemp strains ) for use in various smokable hemp products – specifically, Rebel Hemp Company’s premium hemp pre-rolls.

Licensing agreement with Tommy Chong to manufacture and distribute Tommy Chong’s Cannabis™

  • Full Spectrum Elixir 1:1.
  • The tincture, features a 1:1 ratio of THC to CBD, recognized for its medicinal properties
  • Distributed exclusively by Indus and is anticipated to be in-dispensaries throughout California by March 01, 2020.
  • Anticipating producing up to 25,000 units of  during the 1st 12 months with an estimated retail price of $70 per unit 

LOI with ER71 USA Inc. (“Easyriders”)  an iconic brand with millions of followers globally,  have entered into LOI to complete a joint venture agreement

  • Upon completion of the Joint Venture, Hollister and Easyriders will collaborate on the development and marketing of co-branded hemp based everyday premium product lines.
  • Pre-rolled products using hemp

JV will further explore the development and marketing of additional product SKU’s for hemp-based

  • Edibles
  • Vapes
  • Topicals
  • beverages.

Revenue generated on the co-branded product lines will be shared 50:50 between Easyriders and Hollister. 

Hollister Biosciences Inc. and Veteran Based Tactical Relief Enter into Letter of Intent for Proposed Joint Venture Agreement

  • Upon completion of the Agreement, Hollister and Tactical Relief will collaborate on the development and marketing of cannabis tinctures throughout the California market
  • Branded under Tactical Relief, the first cannabis tincture to be manufactured will feature a 20:1 ratio of THC to CBD, recognized for its medicinal properties in treating PTSD
  • Will be distributed exclusively by Hollister’s distribution partner, Indus Holdings Inc.
Hollister Biosciences Inc. and Tactical Relief Enter into Letter of Intent for Proposed Joint Venture Agreement (CNW Group/Hollister Biosciences Inc.)

Hollister Currently Manufactures The Following Products:

  • hash
  • hash infused products
  • tinctures
  • crumble infused products
  • Pre-rolls           
  • Vape Products   
  • Pet CBD 
  • Cannabis Concentrate   
  • Brewed Hemp Beverages
  • Premium Hemp Pre-Rolls
  • other cannabis products

HashBones

  • Hashbones are a pre-roll made from 75% cannabis flower blended in small batches with 25% bubble hash
  • Results in a more potent pre-roll, also maintains the integrity of the cannabis
  • Terpenes are preserved in the bubble hash production process
  • Bubble hash is made without solvents or chemicals and is one of the cleanest concentrates available on the market
  • Hollister’s trusted and highly rated brand of pre-rolls, sold via third-party retailers

Mighty Meds

  • Acquired Mighty Meds as its vape brand
  • Company’s vape products are manufactured from pure THC distillate and plant-based terpenes and do not use any additives that have been linked to health issues.
  • San Diego based
  • Produces discreet, disposable, health conscious vape cartridges and other products

Purity Petibles

  • Purity Petibles 20:1 CBD pet tincture is manufactured using full spectrum CBD, organic MCT Oil derived from coconuts and chicken flavor
  • The MCT Oil and chicken flavor used in Purity Petibles is food grade

Rebel Tea

  • Brewed with high-quality, American-grown hemp and containing fifteen milligrams of whole-plant full-spectrum phytocannabinoids, Rebel Tea offers consumers a refreshing THC-free beverage. Rebel Tea’s innovative formula features exclusively organic ingredients paired with light flavoring from natural lemon and cane sugar.

NanoPure

NanoPure, nano-emulsified cannabis concentrate which will be sold both:

  • Wholesale as an ingredient for other companies and
  • power products for Hollister Cannabis Co. 

DISTRIBUTION

  • Hollister has an exclusive distribution agreement in place with Indus Holdings (CSE: INDS).
  • Indus is the licensed California distributor that operates the WAYV platform.
  • Indus currently manages all of Hollister’s product fulfilment obligations, allowing Hollister to focus its efforts on production and marketing.
  • Indus provides Hollister with full brand representation by utilizing its 15 sales reps to represent Hollister’s product to the California marketplace. 
  • Through Indus, Hollister’s products are now present in 220 dispensaries throughout California.

US CANNABIS MARKET STATS

CALIFORNIA CANNABIS MARKET STATS

HEMP

The Company intends to move into the hemp market.  While cannabis is still restricted by state regulations, CBD is not. We plan on leveraging the brand by distributing hemp and CBD versions of our products nationwide. We will strive to have the Rebel Hemp Co brand touch every corner of the country.

CORPORATE STRUCTURE

Hollister develops quality branded cannabinoid-based and hemp-based consumer goods and products for large-scale distribution through two companies: Hollister Cannabis Co. and Rebel Hemp Company.

Tags: , , , , , , , ,
Posted in AGORACOM Clients (New), All Recent Posts, Hollister Biosciences | Comments Off on AGORACOM Welcomes Hollister Biosciences With A $20 MILLION LOI Signed To Acquire Venom Extracts With $CDN 16.4 million In Revenue and $CN 2.48 million in EBIDTA

#Apple, #J&J Launch New #Mhealth Study Targeting #Wearables and #AFib SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 5:20 PM on Tuesday, February 25th, 2020

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Apple, J&J Launch New mHealth Study Targeting Wearables and AFib

By Eric Wicklund

  • Apple is partnering with Johnson & Johnson on a new mHealth study to determine whether the Apple Watch and an accompanying app can help reduce the risk of stroke in older Americans.
  • The Heartline Study is open to the more than 40 million seniors enrolled in Medicare
  • Goal is to determine whether the ECG sensor and app on the Apple Watch can accurately detect the presence of atrial fibrillation, a key indicator of stroke susceptibility.

The Heartline Study is open to the more than 40 million seniors enrolled in Medicare. Its goal is to determine whether the ECG sensor and app on the Apple Watch can accurately detect the presence of atrial fibrillation, a key indicator of stroke susceptibility.

“Right now, we rely on symptoms – such as quivering, fluttering or irregular heart rhythm – to detect AFib,” Michael Gibson, MD, CEO of the Baim Institute for Clinical Research, founder of the Perfuse Study Group at Harvard Medical School and a co-leader on the study, said in a story on the J&J website. “But the hope is that a wearable device could detect an irregular heart rhythm earlier, since people may not be able to recognize symptoms without assistance. It could act like a warning light that allows a mechanic to detect whether something’s wrong before the car actually breaks down.”

Gibson will head the study alongside John Spertus, MD, the Daniel J. Lauer/Missouri Endowed Chair in Metabolic and Vascular Disease Research at the University of Missouri at Kansas City.

This study follows on the heels of the Apple Heart Study, to date the largest analysis of mHealth data from a wearable device. Launched in 2017 by the Stanford University School of Medicine, Apple and American Well, the study attracted almost 420,000 participants and laid the groundwork for the viability of ECG sensors for detecting AFib.

“The study’s findings will help patients and clinicians understand how devices like Apple Watch can play a role in identifying atrial fibrillation, a deadly and often undiagnosed disease,” Mintu Turakhia, MD, an associate professor of cardiovascular medicine at Stanford, said when the study’s results were released in 2019. “Additionally, these important findings lay the foundation for further research into the use of emerging wearable technologies in clinical practice and demonstrate the unique potential of large-scale app-based studies.”

But that study raised concerns because it wasn’t focused on one particular population, leading to worries that such digital health tools could cause more harm than good.

This time around, investigators are homing in on a population facing a significant risk of stroke.

“Each year more than 795,000 people have a stroke in the US, and some studies have shown that many people would rather die than live with the aftereffects of a disabling stroke,” Gibson said. “Secondly, we have an aging population, so there are more and more older patients around the world. These are exactly the patients who are at the highest risk of atrial fibrillation, which is associated with a significant increase in the risk of stroke. But the good news is that these strokes may be preventable.”

‘By having the study focus on the highest risk patients, my hope is that we can potentially help participants improve their heart health,” he added.

Participants in the study will use an Apple Watch and Heartline Study app, which alerts the user when the smartwatch detects an irregular heart rhythm and advises him or her to seek advice from a healthcare provider. The app, which also provides information and resources to the user, can be triggered to personalize that information if a care provider confirms an AFib diagnosis or if the user isn’t engaged with the program.

“The decision to take action is the responsibility of the participant, but the Heartline Study app will provide additional prompting and educational materials to help people make informed decisions,” Gibson said.

“I’m excited about this part of the study because, as physicians, we need to get a better handle on how often that lack of action happens,” he added. “While it’s clear that patients often don’t take the medicines they’re prescribed – and, in fact, often don’t even pick them up from the pharmacy – this study could provide more solid data and help us learn more about how often patients don’t respond to warnings about abnormalities in their health.”

In time, he said, researchers hope to understand more about why people might not take part in this type of study and develop patient engagement techniques that promote participation and reduce barriers to care.

Source: https://mhealthintelligence.com/news/apple-jj-launch-new-mhealth-study-targeting-wearables-and-afib

Tags: , , , ,
Posted in CardioComm Solutions | Comments Off on #Apple, #J&J Launch New #Mhealth Study Targeting #Wearables and #AFib SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

4 Reasons Why The EdTech Industry Is Set To Take Off – SPONSOR: BetterU Education Corp. $BTRU.ca $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 4:56 PM on Tuesday, February 25th, 2020
SPONSOR:  BetterU Education Corp. aims to provide access to quality education from around the world. The company plans to bridge the prevailing gap in the education and job industry and enhance the lives of its prospective learners by developing an integrated ecosystem. Click here for more information.

4 Reasons Why The EdTech Industry Is Set To Take Off

  • Education Sector is Ripe for Disruption
  • Increasing User Base of Mobile Phones and Internet
  • The Young Are Leading the Way
  • Personalization of Education  

By: Neetin Agrawal Founder, Dronstudy

With the influx of smart devices, Internet and advanced software, the scope of education is expanding to every nook and corner of India. The impact of edtech on not just the education sector but broadly on the society is applaud-worthy, which is why the edtech sector is also highly popular among aspiring start-ups.

Online learning and courses are growing at a rapid pace as professionals realize the lack of skill-based courses and poor infrastructure in the Indian education system is now affecting their careers. 

In the last few years, an increasing number of entrepreneurs have also realized the potential of edtech. The uptrend will continue, thanks to the Digital India campaign, the cultural importance of education in Indian society, and low mobile data prices.

Private equity and venture capitalfirms are also keenly investing in this sector and not just in K–12 (kindergarten to 12th grade) but also in online courses. Supplemental courses, test preparation, online certification and gamification have vast potential that is yet to be explored. 

Education Sector is Ripe for Disruption

The Indian education system has been following the same traditional approach for decades. Even though the Indian culture has always laid high emphasis on education, yet it has seen a minimal transformation. To reform the country into a digitally empowered nation, the Indian government has also launched the initiative Digital India. 

The education sector is ripe for disruption—ranging from government initiatives to steps taken by educational institutions. The country is seeing a massive wave of revolution in the edtech sector. Schools and universities are embracing digital educational tools, and even offices are encouraging their employees to take up online courses to be more efficient and productive. 

Increasing User Base of Mobile Phones and Internet

The penetration of smartphones and cheap data rates has been a game-changer for the edtechs. Today, there are over 350 million mobile phone users in India, which is expected to double by 2022. With these numbers, there is no doubt that mobile phones and digital devices are the classrooms of the future. 

Online courses, virtual classrooms, digital teaching tools in classes, and through the increasing use of cutting-edge technologies such as virtual reality, artificial intelligence and augmented reality, the delivery and methodology of learning is changing. Not just the learners and educators, but entrepreneurs are becoming increasingly aware of the potential of technology in education.

The Young Are Leading the Way 

The workplaces have changed drastically, and the education system must change along. The edtech sector is helping fill the gaps between the education system and the professional world—it is aiding individuals to develop practical skills in addition to the theory taught in classrooms. 

Edtech entrepreneurs, or edupreneurs, are mostly young minds who are passionate about technology and aspirational. They are revolutionizing the education sector by launching unique initiatives and balancing technology with learning, helping it reach students, teachers and parents across metros, and tier II and III cities.

Personalization of Education 

With technology, the educators (teachers, professors, and educational institutions) will be able to strategize and customize the syllabi as per each student. The various educational programmes today are addressing the distinct interests, learning requirements and aspirations of a learner structure. 

Online courses are offering the masses a flexible and affordable way to acquire new skills. The advancements in education are helping people access education easily, rise above traditional bookish knowledge, and gain a better understanding of a subject through videos, online study material and educational apps with a variety of learning tools. 

Education in India is yet to go a long way, but the edtech sector is overcoming the hurdles one at a time.

Source: https://www.entrepreneur.com/article/346750

Tags: , , , , ,
Posted in All Recent Posts, betterU Education Corp | Comments Off on 4 Reasons Why The EdTech Industry Is Set To Take Off – SPONSOR: BetterU Education Corp. $BTRU.ca $ARCL $CPLA $BPI $FC.ca

INTERVIEW: Hollister $HOLL.ca Signs $20M LOI To Acquire Venom With $16.4M Revenue & $2.48M EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 4:00 PM on Tuesday, February 25th, 2020

At a time when Cannabis stocks are struggling and in a massive state of flux, due to an inability to actually deliver real businesses, Hollister Biosciences (HOLL:CSE) has been quietly building a real business, products, revenue and customers in 220 of California’s 600 dispensaries …. and growing, including California’s #1 hash infused pre-roll “Hashbone”.  

In addition to that, Hollister has also signed LOI’s, JV’s and licensing deals with major partners with massive nationwide and even global audiences launching in the next couple of months.  We’ll save details of those for another day but suffice it to say one of those partners is the world renowned Tommy Chong (of Cheech & Chong) who stated:

“I only partner with the best-in-class companies and I am really pleased to have the Hollister Cannabis Co. bring their amazing Tommy Chong’s Cannabis™ Full Spectrum Elixir to the market for me”.   

If that was all Hollister had going, they’d be in great shape with a super bright future and better than most Cannabis companies (small and large) who can’t even get product out the door.  

BUT THERE’S MORE – THE $20,000,000 ACQUISITION THAT COMES WITH $CDN 16.4M REVENUE & $CDN 2.48M EBITDA  

Earlier today, Hollister announced an LOI to acquire Venom Extracts, one of Arizona’s largest producers of Award-Winning Medical Cannabis Distillate. Just how good is Venom? In 2019, Venom generated $CDN 16.4M in revenue and $CDN 2.48M EBITDA in 2019 (subject to due diligence confirmation) … and all of that was just from the state of Arizona! Venom CEO Mason Cave and his team have aggressive plans to expand its brand and success into other states, including California as it benefits from Hollister’s distribution into 220 dispensaries.  

If you think “growth talk is cheap” (which is often the case), consider the fact that 30% of Venom’s $20,000,000 sale price kicks in if/when revenues hit $CDN 30,000 and $CDN 40,000 …. by December 31, 2021.  In my experience, companies joining forces don’t include such terms if there isn’t a reasonable expectation for hitting those numbers.  It doesn’t guarantee it but you can bet they have good reason to believe Venom sales will get to one or both of those numbers in just 21 months from now.  

If you’re looking for Cannabis companies that are going to survive and thrive over this next decade, then grab your favourite beverage and watch this interview with Hollinger President, Alex Somjen.  

We loved what we heard and look forward to your feedback in Hollister’s CEO Verified Forum below!

https://agoracom.com/ir/HollisterBiosciences

Tags: , , , , , , ,
Posted in All Recent Posts, Featured | Comments Off on INTERVIEW: Hollister $HOLL.ca Signs $20M LOI To Acquire Venom With $16.4M Revenue & $2.48M EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Empower Clinics $CBDT.ca to Create #Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 6:10 AM on Tuesday, February 25th, 2020
  • Company intends to utilize its database of 165,000 patients to further psilocybin research, develop new products and partner with global leaders in the field
  • “Empower is uniquely positioned to immediately impact research, develop new products and bring advancements to plant-based therapies, under a framework of rapidly increasing awareness and a movement toward decriminalization of psychedelic treatment options.” said Steven McAuley, Chairman & CEO of Empower

VANCOUVER, BC / February 25, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTC:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented life sciences company is pleased to announce it intends to leverage its existing clinic network, the developing franchise brand, its 165,000 patients and product development capability, to create psilocybin and psychedelics subsidiaries.

The Company has been conducting market research on advancements in psilocybin and psychedelics in North America and globally, along with building the business case internally on how to create greater shareholder value, utilizing Company assets that include clinics, patients, physicians and technology.

“There is an undeniable mental health crisis in our country and around the world, that has an ever-increasing, devastating affect on our society.” said Steven McAuley, Chairman & CEO of Empower. “Empower is uniquely positioned to immediately impact research, develop new products and bring advancements to plant-based therapies, under a framework of rapidly increasing awareness and a movement toward decriminalization of psychedelic treatment options.”

Studies conducted by nationally and internationally recognized medical institutions indicate that psilocybin has shown efficacy, tolerability, and safety in the treatment of a variety of mental health conditions, including but not limited to addiction, depression, anxiety disorders, and end-of-life psychological distress.

“Over the past seven years, we have assisted over one hundred thousand patients obtain access to alternative health care and medicinal cannabis. The provision of legal access to psilocybin therapies are perfectly in-line with our philosophy of providing a Scientific Approach to Alternative Medicine™“, said Dustin Klein, SVP Business Development and Director, Empower Clinics Inc. “Clinical trials have shown that psilocybin therapies provide tremendous help with conditions we see everyday in our clinics. It is our responsibility, to make sure we are providing the most up-to-date alternative therapies to our patients and our community.”

The mental health crisis could cost the world $16 trillion by 2030 and according to Future Market Insights; the global behavioral health (non-pharmacological) market is expected to be valued at US$156 billion by 2028.

The United States Food and Drug Administration has determined that preliminary clinical evidence indicates psilocybin may demonstrate substantial improvement over other available therapies for treatment-resistant depression; and granted a Breakthrough Therapy designation for a treatment that uses psilocybin as a therapy for such depression.

The Company also announces it has issued to Haywood Securities Inc., 4,000,000 common shares of the Company (the “Work Fee Shares”) under the financial advisory agreement dated September 25, 2019 (the “Agreement”) based on Haywood Securities Inc. completing the final written SWOT analysis. The shares issued are priced at fair market value of the common shares of the Corporation as at the date of issuance of the Work Fee Shares.

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower Clinics $CBDT.ca to Create #Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Hollister Biosciences $HOLL.ca Signs Letter of Intent to Acquire Venom Extracts With $16.4 Million In Revenue And $2.48 Million EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 6:02 AM on Tuesday, February 25th, 2020
  • Company signed a Letter of Intent to acquire Venom Extracts
  • One of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.
  • Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges.

Hollister Biosciences Inc., the creator of California’s #1 hash-infused pre-roll HashBone, enters into Letter of Intent to acquire Venom Extracts, one of Arizona’s largest producers of award-winning medical cannabis distillate and related products

VANCOUVER, Feb. 25, 2020 – Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a vertically integrated cannabis branding company with products in 220 dispensaries throughout California, is pleased to announce that the Company signed a Letter of Intent (“LOI“) on February 20th, 2020 to acquire Venom Extracts ( “Venom“), one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.

HIGHLY ACCRETIVE $20,000,000 ACQUISITION

For the year ended December 31, 2019, Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges. Hollister cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by Venom management. Though Hollister believes the figures to be highly reliable, their audit will be part of the due diligence before closing.   

The all stock purchase price is anticipated to be CDN$ 20,000,000, with 70% to be paid upfront and 30% to be paid upon milestone achievements. The acquisition is expected to close by March 31, 2020 subject to normal course due diligence. 

 “Venom has established itself as a leading extraction operation with a prominent brand in the Arizona marketplace”, said Carl Saling, Founder and CEO of Hollister Biosciences Inc.  “We feel this acquisition will present a great deal of opportunity for synergy between Hollister and Venom, providing avenues for both companies into the Arizona, California and additional marketplaces for cannabis products.  Venom Extracts has a highly skilled and experienced management team with a track record for operational excellence.  This transaction is highly accretive and represents a fundamental part of the future growth of both companies.”

LOI TERMS

The terms of the LOI, which will be formalized by a definitive agreement on closing, are as follows:

  • The Company will acquire Venom Extracts for CDN$20,000,000 with such payment to be issued in Hollister common stock (the “Payment Shares“)
  • The stock price will be determined based on the greater of:
    • The 14-day VWAP (Volume Weighted Average Price) capped at $0.25 subsequent to announcing the transaction and $0.20
  • Once the share price is established, 70% of the Payment Shares will be issued upon closing of the transaction, subject to hold periods.
  • The remaining 30% of the Payment Shares will be issued when and if the following milestones have been met on or prior to December 31st, 2021:
    • 20% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 30,000,000 (calculated in accordance with IFRS from January 1, 2020).
    • 10% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 40,000,000(calculated in accordance with IFRS from January 1, 2020).

“We are very pleased to be entering into this transaction with Hollister”, shared Mason Cave, CEO of Venom Extracts.  “The opportunities for resource and capability sharing between the two companies are plentiful.  This also represents a more expeditious avenue for us into the large and rapidly growing California marketplace.  Hollister has an excellent management team in place and has established itself as a sought-after brand house of popular cannabis and hemp products in California.  We feel that our contribution on the extraction side will help diversify Hollister’s product offering and continue to build out the brand equity of both companies across multiple state and eventually global marketplaces”

In association with the arm’s length transaction, Hollister will not be assuming any long-term debt, a new control position will be created and there is no change in Management, or the Board of Directors of Hollister being contemplated at this time.

Finder’s fees will be payable in accordance with the policies of the Canadian Securities Exchange.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a vertically integrated cannabis company with multiple, high-quality products now carried in 220 of Indus Holdings (CSE: INDS), Hollister’s exclusive distribution partner’s 600 dispensaries. This level of penetration is expected to grow as the Company accelerates its seed to shelf, high margin business and product development model.

Capitalizing on this success, Hollister’s vision is to become the sought-after premium brand portfolio of innovative, high quality cannabis across multiple states and hemp products nationwide.

Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California, the birthplace of the “American Biker” from which we embrace the outlaw roots of Hollister to drive our Company fearlessly down the road of success.

Products from Hollister Cannabis Co. include HashBone, the brand’s premier artisanal hash-infused pre-roll ranked as California’s #1 hash infused pre-roll, along with solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures.

Website:  www.hollistercannabisco.com 

About Venom Extracts

Venom Extracts is one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.  With an experienced management team and unparalleled reputation for quality, Venom Extracts prides itself as a differentiated extraction company by producing legal Marijuana products at a price point that allows retailers to generate higher profits.  Focused on proprietary efficiencies, the Company is able to produce more product per square foot than its competition, maintaining lower costs and risks than a typical extraction company. The company’s expansion strategy is centered on entering new markets/states that are approved for medical cannabis use and/or approved or have a reasonable expectation to be approved for recreational use in the near future. 

Website:  www.venomextracts.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile onwww.sedar.com

million-ebitda-301010229.html

SOURCE Hollister Biosciences Inc.

Tags: , , , , , ,
Posted in Featured, Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca Signs Letter of Intent to Acquire Venom Extracts With $16.4 Million In Revenue And $2.48 Million EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

INTERVIEW: As Cannabis Companies Struggle, $MOTA.ca Delivers $29M Revenue, $3.6M EBITDA – And That’s Just The Start $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 4:03 PM on Monday, February 24th, 2020

In 1948, Winston Churchill said, “Those who fail to learn from history are condemned to repeat it”.  Unfortunately, many Cannabis companies aren’t historians and are repeating the dot-com to dot-bomb cycle of raising tons of money but no clue how to build a real business with it.

You know what else we learned from that cycle?  Web 2.0 was the birth of companies with real business plans, products, customers and revenues.  They went on to dominate the next 20 years.

Enter MOTA Ventures (MOTA:CSE), who has become a leader in online CBD sales into the North American market, thanks to an e-commerce “engine” built by CEO Ryan Hoggan and his team over the past few years at Unified Funding.  That engine is so powerful that is has racked up over $200 MILLION in sales from over 1 million paying customers over a number of products, including CBD sales of $25 MILLION by “First Class CBD”, which was acquired by MOTA for $32 MILLION.

As the new CEO of MOTA, Ryan is bringing that ecommerce engine into the Company to further drive CBD sales into the US market, as well as, Europe.  As an online company ourselves, we can pretty easily spot companies that are just trying to piggy back “e-commerce”.  Ryan is the real deal.  As you will hear in this interview, he has already achieved monster e-commerce success with the likes of Boeing, Daimler and the Lakers basketball team on over 100 health and wellness products.

The best part for MOTA shareholders?  Ryan is highly motivated to continue with his successful ways because Unified Funding can earn an additional $15 MILLION if First Class CBD achieves sales of $62 MILLION.  In my experience, companies don’t put bonuses into contracts unless they both believe there is a reasonable belief they can be achieved. Will he hit $62M?  Or fall short at the other 2 milestones of $52M and $42M?

Watch this interview and you be the judge.  Either way, MOTA shareholders should get their popcorn ready because Ryan has already proven he’s leading MOTA into the Cannabis 2.0 phase.  Success is already here, now its just a question of how high MOTA will fly.

Watch this interview and share it with every investor you know!

Tags: , , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, Mota Ventures Corp. | Comments Off on INTERVIEW: As Cannabis Companies Struggle, $MOTA.ca Delivers $29M Revenue, $3.6M EBITDA – And That’s Just The Start $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

North Bud Farms $NBUD.ca Announces the Appointment of Jeffrey Stoss as Chief Financial Officer $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 9:15 AM on Monday, February 24th, 2020
  • Announced the appointment of Jeffrey Stoss as Chief Financial Officer of the Company.
  • Mr. Stoss brings more than 17 years of finance experience to his role at NORTHBUD, with a particular specialty in high-growth environments.

TORONTO, Feb. 24, 2020 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company“) is pleased to announce the appointment of Jeffrey Stoss as Chief Financial Officer of the Company.

“We are pleased to welcome Jeff to our dynamic team as NORTHBUD is at an exciting time in its development,” stated Sean Homuth, CEO of North Bud Farms Inc. “Jeff brings specialty experience in accounting and finance having worked with and advised many public companies over the years in both Canada and the United States. His leadership and expertise will be essential in executing our strategic plan and taking the Company to its next level of growth.”

Mr. Stoss brings more than 17 years of finance experience to his role at NORTHBUD, with a particular specialty in high-growth environments. He is the co-founder and Chief Operating Officer of the outsourced finance services firm, Positive Venture Group Inc.  He has previously served as CFO for publicly-traded companies and technology start-ups. Mr. Stoss has professional accountant designations in both Canada and the United States.

RSU Grants

On February 20, 2020, the Company’s board of directors approved the grant of 361,000 restricted share units (“RSUs”) to certain directors and consultants of the Company. The RSUs vest in four equal tranches starting three months from the date of grant. Each vested RSU entitles the holder thereof to receive one common share of the Company upon delivery of an exercise notice, in accordance with the Omnibus Plan.
   
About North Bud Farms Inc.

NORTHBUD, through its U.S. subsidiary Bonfire Brands USA, has acquired cannabis production facilities in California and Nevada. The Salinas, California 11-acre farm is actively cultivating cannabis in its 60,000 sq. ft. of licensed greenhouse production space. The Reno, Nevada property is located on 3.2 acres of land which was acquired through the acquisition of Nevada Botanical Science, Inc., a world class cannabis production, research and development facility with 5,000 sq. ft. of indoor cultivation which holds medical and adult use licenses for cultivation, extraction and distribution. Through its wholly-owned Canadian subsidiary, GrowPros MMP Inc., the Company is pursuing a license under The Cannabis Act, to cultivate in its state-of-the-art purpose-built cannabis production facility located on 135 acres of agricultural land in Low, Quebec, Canada.

For more information visit: www.northbud.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements and information included in this press release that, to the extent they are not historical fact, constitute forward-looking information or statements (collectively, “forward-looking statements”) within the meaning of applicable securities legislation.  Forward-looking statements, include but are not limited to those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management.

Forward-looking statements, including those regarding the success of the Company’s licence application, the Company’s ability to execute its strategic plan, conditions in the cannabis market, the Company entering agreements in connection with the B2B supply of cannabis and the Company’s transition into a revenue-generating operational phase of development are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements.  Such risks and uncertainties include, among others, the risk factors included in the Company’s final long form prospectus dated August 21, 2018, which is available under the Company’s SEDAR profile at www.sedar.com. Accordingly, readers should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected] 

Tags: , , , , ,
Posted in North Bud Farms Inc | Comments Off on North Bud Farms $NBUD.ca Announces the Appointment of Jeffrey Stoss as Chief Financial Officer $CGC $ACB $APH $CRON.ca $OGI.ca

« Older Entries
Newer Entries »